May 22, 2023 07:22 AM EDTUpdated 07:42 AM
R&D
Pharma

Al­ny­lam up­dates its pitch for ex­pand­ed On­pat­tro la­bel with 18-month PhI­II da­ta

Katherine Lewin

News Reporter

Al­ny­lam Phar­ma­ceu­ti­cals is so pleased with 18-month da­ta from its Phase III tri­al in­ves­ti­gat­ing On­pat­tro as a treat­ment of AT­TR car­diomy­opa­thy that it

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

A service from the Financial Times